Estrella Immunopharma, Inc.ESLANASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+102.7%
5Y CAGR+77.9%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+102.7%/yr
Annual compound
5Y CAGR
+77.9%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
17.8x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$13.06M+47.7%
2024$8.85M+21.0%
2023$7.31M+365.8%
2022$1.57M-6.9%
2021$1.69M+129.7%
2020$733693.00-